The FDA on September 26, 2019 approved DARZALEX® for adult patients with Multiple Myeloma in combination with VELCADE® (Bortezomib), THALOMID® (Thalidomide), and Dexamethasone in newly diagnosed patients who are eligible for Autologous Stem Cell Transplant (ASCT). DARZALEX® is a product of Janssen Biotech, Inc.
Bottom Ad
Advertisement
Subscribe
